David Hong

David Hong

Company: MD Anderson Cancer Center

Job title: Deputy Chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine


Panel Discussion: Now We Have Successfully Targeted RAS G12C, What’s Next? 5:00 pm

As we close out two days dedicated to critical updates and project successes from across this community, this panel will dive into a discussion considering what is next for therapeutics targeting RAS-mutant cancers. After 40 years of dedicated science and significant progress, it is critical we expand the landscape of RAS targeted therapies beyond G12C…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.